{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/neutropenic-sepsis/background-information/definition/","result":{"pageContext":{"chapter":{"id":"4adba361-ab85-5502-b0b7-ccd33f58b0f9","slug":"definition","fullItemName":"Definition","depth":2,"htmlHeader":"<!-- begin field e01dec1a-de1a-41cd-a55b-4ff8d1f8f42f --><h2>What is it?</h2><!-- end field e01dec1a-de1a-41cd-a55b-4ff8d1f8f42f -->","summary":"","htmlStringContent":"<!-- begin item dda3d551-2ce6-4126-afcd-b51fce28aa97 --><!-- begin field f847408e-dd49-4258-b339-5ecfbe60239b --><ul><li><strong>Sepsis is a syndrome defined as life-threatening organ dysfunction due to a dysregulated host response to infection,</strong> according to the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/neutropenic-sepsis/references/\">Shankar-Hari, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/neutropenic-sepsis/references/\">Singer, 2016</a>].<ul><li>Septic shock is a subset of sepsis, which describes circulatory, cellular, and metabolic abnormalities which are associated with a greater risk of mortality than sepsis alone.<ul><li>In a hospital setting, septic shock is defined as sepsis with persisting hypotension despite fluid correction and inotropes (requiring vasopressors to maintain a mean arterial pressure [MAP] of 65 mmHg or more), <em>and</em> hyperlactataemia with a serum lactate level of greater than 2 mmol/L, where MAP is the driving pressure of tissue perfusion [<a class=\"bibliography-reference internal-reference\" href=\"/topics/neutropenic-sepsis/references/\">Singer, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/neutropenic-sepsis/references/\">Daniels, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/neutropenic-sepsis/references/\">Rhodes, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/neutropenic-sepsis/references/\">RCGP, 2018</a>].</li><li>See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/sepsis/\">Sepsis</a> for more information.</li></ul></li></ul></li><li><strong>Neutropenic sepsis is a potentially life-threatening complication of anticancer and other immunosuppressive drug treatment</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/neutropenic-sepsis/references/\">Warnock, 2016</a>]. It is defined as a temperature of greater than 38°C or any symptoms and/or signs of sepsis, in a person with an absolute neutrophil count of 0.5 x 10<sup>9</sup>/L or lower, according to the National Institute for Health and Care Excellence (NICE) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/neutropenic-sepsis/references/\">NICE, 2012</a>].<ul><li>The definition of neutropenia using absolute neutrophil count varies in the literature [<a class=\"bibliography-reference internal-reference\" href=\"/topics/neutropenic-sepsis/references/\">NICE, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/neutropenic-sepsis/references/\">Ku, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/neutropenic-sepsis/references/\">Warnock, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/neutropenic-sepsis/references/\">White, 2017</a>]. The risk of clinically significant infection and sepsis increases as the neutrophil count decreases to less than 0.5 x 10<sup>9</sup>/L [<a class=\"bibliography-reference internal-reference\" href=\"/topics/neutropenic-sepsis/references/\">Warnock, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/neutropenic-sepsis/references/\">White, 2017</a>].</li></ul></li><li><strong>Febrile neutropenia is the most common complication of anticancer treatment, and describes the presence of fever in a person with neutropenia </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/neutropenic-sepsis/references/\">Morgan, 2018</a>]<strong>.</strong> The exact definition of febrile neutropenia varies in the literature.<ul><li>The European Society for Medical Oncology (ESMO) defines febrile neutropenia as an oral temperature of more than 38.3°C, or two consecutive readings of more than 38°C for 2 hours, and an absolute neutrophil count of 0.5 x 10<sup>9</sup>/L or lower, or expected to fall below this level [<a class=\"bibliography-reference internal-reference\" href=\"/topics/neutropenic-sepsis/references/\">Klastersky, 2016</a>].</li><li>The Infectious Disease Society of America (IDSA) defines fever in people who are neutropenic as a single oral temperature of greater than 38°C for more than one hour [<a class=\"bibliography-reference internal-reference\" href=\"/topics/neutropenic-sepsis/references/\">Taplitz, 2018</a>].</li></ul></li></ul><!-- end field f847408e-dd49-4258-b339-5ecfbe60239b --><!-- end item dda3d551-2ce6-4126-afcd-b51fce28aa97 -->","topic":{"id":"c8aa50da-234b-5d4d-b2b3-1ae1d89115e0","topicId":"08d261eb-f269-42a7-801b-2cfddf69a31c","topicName":"Neutropenic sepsis","slug":"neutropenic-sepsis","lastRevised":"Last revised in March 2020","chapters":[{"id":"ade08997-70b7-5f71-ace1-e47c80bdc07a","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"999bcfa1-3c00-58e5-8186-5b889008a21f","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"9ff15809-1783-50bc-8cc4-5fb56eb08252","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"1c09fe06-1c69-51ad-8cc6-a0823851753f","slug":"changes","fullItemName":"Changes"},{"id":"1914dca9-ff88-5330-9b92-27f7df59493c","slug":"update","fullItemName":"Update"}]},{"id":"ed21973f-408a-58e8-912b-7bd2b9d0b718","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"58b41c14-2b33-5d1a-b538-099b3fca97fa","slug":"goals","fullItemName":"Goals"},{"id":"c647afae-0cce-504a-b6c3-2af1cf1df43b","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"9ef3011a-bd82-5da3-ad4c-e33e63dfb333","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"1ff2a9b1-3f7b-5c06-8db0-0061ed24ddb4","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"eea45e78-ce2a-5043-85e2-4acda94fa67e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"167786d0-fb09-53a6-b02d-05105c74f541","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"bafe86b3-b06d-52ce-9da2-4373bfa1b619","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"4adba361-ab85-5502-b0b7-ccd33f58b0f9","slug":"definition","fullItemName":"Definition"},{"id":"048bb40e-2b5d-5e2d-8205-4cb6c5986b71","slug":"causes","fullItemName":"Causes"},{"id":"53c0b23f-7fa2-5824-b31e-6277f40216a8","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"751f6798-f767-50f9-b2b5-b23b45bc02cd","slug":"prevalence","fullItemName":"Prevalence"},{"id":"1b791a2a-8fd9-5d7c-8986-d1e27bf8e0dc","slug":"complications","fullItemName":"Complications"},{"id":"432b2287-33da-5d24-bf96-4c7e3cf898a9","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"2422aa1e-8340-5487-8466-e27286e03762","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"338f02ac-53b8-56c4-a0d0-df9873cabe95","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"292306b5-1418-5247-90d7-fe7ddd283226","slug":"assessment","fullItemName":"Assessment"}]},{"id":"a7a279c8-f7ee-50ec-90b2-5441d36ecceb","fullItemName":"Management","slug":"management","subChapters":[{"id":"28f8b375-c46b-5444-98d8-f753fae4bcfa","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"5a36b1f2-e382-5001-8945-0cef6e53ec83","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"c0e91f63-5078-5363-b15a-7db7cc483396","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"740f1b28-1eb9-5160-9dd6-5a1e00f5e8c1","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"17c51bf6-cc58-58c7-8a0a-d6caed83c5b6","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"c53a0347-9a44-5b20-b1b4-1adfa5b3f959","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"460cc4fe-21c5-57de-9ae3-4c27bc1ab338","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"a88ff1aa-1ddd-5785-a592-ebfafff8da3e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"8205950b-1254-5a4b-a51a-4a887c9da60d","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"bafe86b3-b06d-52ce-9da2-4373bfa1b619","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}